China Construction Bank cuts deposit rates
BEIJING, May 20 (Reuters) - China Construction Bank (601939.SS), opens new tab cut deposit rates on Tuesday, part of an expected move by Chinese state-owned banks to alleviate shrinking interest margins at lenders as Beijing rolls out sweeping monetary easing measures to aid the broad economy.
The bank reduced deposit rates by 5-25 basis points for some tenors, according to rates shown on its mobile app.
Reuters reported on Monday that China's major state banks plan to cut their deposit rates from Tuesday, citing sources.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
35 minutes ago
- Reuters
Chinese firms in talks to join group to buy Li Ka-shing's ports, Bloomberg News reports
June 12 (Reuters) - Chinese ports operator China Cosco Shipping Corporation is among the firms in talks to participate in a global consortium seeking to buy 43 ports from billionaire Li Ka-shing-owned CK Hutchison ( opens new tab, Bloomberg News reported on Thursday. CK Hutchison said last month that Mediterranean Shipping Company, run by the family of Italian billionaire Gianluigi Aponte, was the main investor in a group seeking the portfolio of ports, which includes two near the Panama Canal, for $22.8 billion. Negotiation for the deal that covers 43 ports in 23 countries is on an exclusive basis between CK Hutchison and the consortium for 145 days until July 27. Adding Chinese investors to the consortium emerged as one of the options after high-level talks in Switzerland last month between Chinese and U.S. officials, the Bloomberg report said. China Cosco Shipping Corp is among the state-backed companies in talks with the consortium run by the Aponte family, the report said. CK Hutchison and China Cosco Shipping didn't immediately respond to Reuters requests for comment. Reuters could not immediately verify the report. The deal has been through weeks of global scrutiny and criticism in China and the U.S. over CK Hutchison's plan to sell the ports to a consortium, previously led by U.S. investment firm BlackRock (BLK.N), opens new tab. BlackRock remains part of the group.
Reuters
2 hours ago
- Reuters
Japan and US explored possibility of trade deal, Japan trade negotiator says
June 13 (Reuters) - Japan and the U.S. on Friday explored the possibility of a trade agreement, Japan's top tariff negotiator, Ryosei Akazawa, told a briefing, while refraining from commenting how close they are to reaching a deal. "We had a very detailed exchange and explored the possibility of a trade agreement," Akazawa told reporters after he met with U.S. Treasury Secretary Scott Bessent and Commerce Secretary Howard Lutnick separately in Washington in a sixth round of tariff negotiations. It is likely to be the last round before Prime Minister Shigeru Ishiba and U.S. President Donald Trump are to meet in Canada on the sidelines of the Group of Seven leaders' summit, where Japan has been hoping to clinch a deal. Akazawa refrained from commenting on whether the talks have matured enough to reach an agreement, saying a deal is possible only when the leaders of both countries approve everything as a package. He also declined to comment on the chance of Ishiba and Trump reaching an agreement at their upcoming meeting. Japan faces a 24% tariff rate starting in July unless it can negotiate a deal with the U.S. It is also scrambling to find ways to get Washington to exempt its automakers from 25% tariffs on automobiles, Japan's biggest industry.
Daily Mail
4 hours ago
- Daily Mail
AstraZeneca in deal with China firm worth up to £4bn
AstraZeneca has agreed a deal that could be worth almost £4billion with a Chinese company to use AI in the production of new treatments for chronic diseases. Britain's largest listed company announced the tie-up with biotech firm CSPC Pharmaceuticals following controversy over its involvement in China. The pharmaceuticals giant will pay CSPC an upfront fee of £81m while a total further payment of up to £3.8billion is available if the drugs reach development and sales-related milestones. AstraZeneca has been ploughing cash into the country, including announcing a £1.8billion research and development hub in the capital Beijing. The firm's former boss in China, Leon Wang, was arrested in October and is still thought to be in detention. More recently, former Tory leader Sir Iain Duncan Smith has accused the pharma giant of 'turning a blind eye to the nature of the Chinese government'. AstraZeneca boss Sir Pascal Soriot said in February: 'We all think about Leon and miss him, but the reality is we are not able to talk to him. We are not allowed.'
